Clinical Trial Update: A Study of the Safety and Efficacy of Vigam® Liquid in Patients With Primary or Secondary Antibody Deficiency [Phase 4]

View source ↗

Summary

Phase 4 trial assessing safety and efficacy of Vigam® Liquid in patients with primary or secondary antibody deficiency completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody Deficiency

Drugs mentioned

• Vigam® Liquid

Snippet

Sponsor: Bio Products Laboratory | Conditions: Primary or Secondary Antibody Deficiency | Phase 4 | Status: COMPLETED